NYSE · BRKR
Healthcare · Medical - Devices
$57.08
Down-$0.19 (-0.33%)
Updated Aug 31, 2026, 4:25 PM
SID Score
6.0/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
BRKR closed at $57.08 after 20 trading sessions, down 11.24% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 28, 2026 | $58.68 | $59.21 | $56.845 | $57.08 | 1.93M |
| Aug 27, 2026 | $58.13 | $59.515 | $57.605 | $59.25 | 2.43M |
| Aug 26, 2026 | $56.26 | $57.555 | $56.26 | $57.06 | 2.53M |
| Aug 25, 2026 | $57.38 | $58.19 | $56.00 | $56.85 | 1.63M |
| Aug 24, 2026 | $59.01 | $59.105 | $56.90 | $56.98 | 1.17M |
| Aug 21, 2026 | $59.60 | $60.305 | $58.06 | $59.56 | 3.2M |
| Aug 20, 2026 | $57.07 | $61.41 | $57.07 | $59.92 | 1.41M |
| Aug 19, 2026 | $56.95 | $61.835 | $56.95 | $58.65 | 1.91M |
| Aug 18, 2026 | $56.98 | $58.58 | $56.80 | $56.86 | 1.55M |
| Aug 17, 2026 | $57.23 | $58.15 | $56.90 | $57.67 | 1.81M |
| Aug 14, 2026 | $57.60 | $58.22 | $56.72 | $57.70 | 1.23M |
| Aug 13, 2026 | $59.27 | $59.735 | $57.5743 | $57.93 | 1.75M |
| Aug 12, 2026 | $57.13 | $59.28 | $56.73 | $59.27 | 2.31M |
| Aug 11, 2026 | $56.06 | $57.495 | $55.50 | $57.02 | 1.77M |
| Aug 10, 2026 | $53.14 | $56.56 | $53.14 | $56.32 | 2.5M |
| Aug 7, 2026 | $52.02 | $53.47 | $51.20 | $53.41 | 2.11M |
| Aug 6, 2026 | $51.38 | $51.87 | $50.78 | $51.27 | 1.91M |
| Aug 5, 2026 | $49.815 | $52.94 | $48.63 | $52.47 | 4.8M |
| Aug 4, 2026 | $54.07 | $56.365 | $50.12 | $50.30 | 8.88M |
| Aug 3, 2026 | $62.09 | $64.47 | $61.35 | $64.31 | 2.44M |
The latest Smart Investors Daily articles mentioning BRKR.
BRKR research
Company profile and research snapshot.
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates in segments, namely, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from United States.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 5, 2026 | Citigroup | Neutral | — |
| Jul 8, 2026 | Citigroup | Neutral | — |
| Jul 7, 2026 | Leerink Partners | Outperform | — |
| Jun 29, 2026 | Guggenheim | Buy | — |
| Jun 24, 2026 | Barclays | Overweight | — |
No generated briefing is available yet.
Yahoo · Aug 21, 2026
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.
Yahoo · Aug 13, 2026
Bruker’s second quarter results prompted a significant negative market reaction, with shares declining sharply following the release. Management identified several factors behind the top-line shortfall, notably the ongoing weakness in U.S. academic and government funding and revenue timing delays in certain deep tech areas, such as semiconductor metrology tools. CEO Frank Laukien described the organic growth as “solid in many life science end markets,” but highlighted that softness in U.S. acade
Yahoo · Aug 11, 2026
Semiconductor metrology and energy research orders surge over 50% organically.
Yahoo · Aug 11, 2026
BOSTON, August 11, 2026--Bruker Corporation (Nasdaq: BRKR) today announced an expanded strategic collaboration with Atinary Technologies Inc., the pioneer of Self-Driving Labs® technologies and AI-driven R&D with applications in pharmaceuticals, chemicals, energy, and materials. Bruker also made a minority investment in Atinary. Financial details were not disclosed.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BRKR.
